Cancer of the anal canal is an uncommon malignancy comprising 2% of all gastrointestinal malignancies; most of these cancers are of the squamous cell histologic subtype (Jemal et al., 2008; Bilimoria et al., 2009; Horner et al., 2009). In most cases, patients present with localized disease that is often curable with concurrent chemoradiation therapy, reserving abdominal perineal resection for salvage therapy. Unfortunately, a minority of patients (12%) will have metastatic disease at initial presentation (Ryan & Willet, 2001; Horner et al., 2009). Due to the lack of evidence-based data and an unknown optimal duration of therapy, treatment decisions are often founded on more common squamous cell carcinomas (SCCs) such as cervical and lung cancer.

Limited Data to Guide Treatment
===============================

In this article, we present the case of a patient with metastatic squamous cell carcinoma of the anal canal that progressed shortly following chemoradiation therapy with curative intent. A key point in this patient's treatment history was the 3-week treatment delay during her concurrent chemoradiation therapy. It is well known that treatment delays should be minimized as much as possible during radiation therapy of the anal canal, and that significant delays negatively impact patient outcome (Graf et al., 2003). In addition, recent data from the phase III ACT II trial have shown no additional benefit in disease-free or overall survival for adjuvant fluorouracil (5-FU)-based chemotherapy following definitive chemoradiation therapy for curative intent (James et al., 2009).

Because metastasis from squamous cell carcinoma of the anal canal is infrequent, there are limited data to guide treatment recommendations (Table 1). The most frequently reported systemic chemotherapy regimen is 5-FU/cisplatin, which has successfully shown a partial response rate as high as 50% and a complete response rate of 15% when used to treat locally recurrent or metastatic disease (Deniaud-Alexandre et al., 2003; Ajani et al., 2008; Eng & Pathak, 2008; Jemal et al., 2008; James et al., 2009; Lynch et al., 2010). In our patient's case, 5-FU/cisplatin was provided as an alternative due to her platinum-naive status. A well-known radiation sensitizer, 5-FU/cisplatin was provided for palliation of pain due to the primary tumor with the interim development of distant metastatic disease.
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Trials in Cancers of Similar Histologic Subtype
===============================================

Other chemotherapy regimens considered for our patient were largely based on data extrapolated from other cancers of similar histologic subtype, i.e., non--small cell lung cancer (NSCLC) and head and neck cancer (Table 2). Unfortunately, the combination of carboplatin/paclitaxel resulted in our patient's continued distant disease progression. Therefore, we chose to pursue the therapeutic recommendation of the vinorelbine, cisplatin, and cetuximab (VCC) regimen based on data from a randomized phase II study of cisplatin and vinorelbine with or without weekly cetuximab as first-line therapy for NSCLC (Rosell et al., 2008). The vinorelbine/cisplatin combination is an accepted regimen for NSCLC, and in this phase II study the addition of cetuximab increased the response rate (35% vs. 28%), the median progression-free survival (5.0 vs. 4.6 months, HR = 0.71), and the median overall survival (8.3 vs. 7.3 months, hazard ratio = 0.71) (Rosell et al., 2008; Van Damme et al., 2008). The pivotal phase III FLEX trial (vinorelbine/cisplatin with or without cetuximab) validated the phase II findings in patients with treatment-naive stage IIIB/IV NSCLC. Those who received the cetuximab combination were found to have superior overall survival (11.3 vs. 10.1 months, *p* = .044) and response (36% vs. 29%, *p* = .010) (Pirker et al., 2009).
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A second phase III trial (BMS099) evaluated the role of epidermal growth factor receptor (EGFR) inhibition in treatment-naive patients to carboplatin (AUC = 6) and either paclitaxel (225 mg/m^2^) or docetaxel (75 mg/m^2^) with a randomization to weekly cetuximab (Lynch et al., 2010). The investigators failed to fulfill the primary endpoint of progression-free survival (*p* = .236) but were able to determine improved response rate (26% vs. 17%, *p* = .007) for the investigational arm. Based on the premise of these studies, EGFR inhibition in combination with chemotherapy seems promising. Additional studies should be pursued to determine predictive markers of response. Unlike in colorectal cancer, the presence of the *KRAS* mutation does not appear to exist in SCC of the anal canal (Van Damme et al., 2008). However, extensive molecular marker analysis is limited at this time (Alvarez et al., 2006; Ajani et al., 2008).

Conclusions
===========

We believe this to be the first case study reported using the VCC combination in metastatic SCC of the anal canal. We recognize that a small series of case studies have been reported using cetuximab as a single agent or in combination with irinotecan as approved for use in metastatic colorectal adenocarcinoma with mild therapeutic benefit (Ajani et al., 2010). In this heavily pretreated patient, the short course of the VCC chemotherapy regimen resulted in a significant response to therapy and was well tolerated. Our treatment indicates the potential benefits of vinorelbine/cisplatin when combined with EGFR inhibition in the setting of locally recurrent or metastatic squamous cell carcinoma of the anal canal. EGFR inhibition has great promise in the treatment of metastatic squamous cell carcinoma of the anal canal, and in our patient's case, was tolerated well.
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